Loading...
XNAS
FEMY
Market cap11mUSD
Jul 09, Last price  
3.85USD
1D
-2.78%
1Q
-51.51%
IPO
-98.23%
Name

Femasys Inc

Chart & Performance

D1W1MN
XNAS:FEMY chart
P/E
P/S
5.07
EPS
Div Yield, %
Shrs. gr., 5y
13.62%
Rev. gr., 5y
17.18%
Revenues
2m
+40.77%
929,0641,037,9181,179,6891,206,2181,071,9701,629,1082,293,313
Net income
-19m
L-1.00%
-11,271,948-6,914,992-7,537,845-11,394,170-14,247,124-18,816,628-18,627,887
CFO
-19m
L-3.87%
-11,005,996-4,933,015-7,930,785-10,731,973-11,280,546-19,444,009-18,690,565

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
IPO date
Jun 18, 2021
Employees
34
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT